{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:12:13Z","timestamp":1789924333781,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.msard.2022.104459","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T19:59:14Z","timestamp":1670529554000},"page":"104459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence"],"prefix":"10.1016","volume":"69","author":[{"given":"Celia","family":"Oreja-Guevara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.","family":"Celius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Kubala","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Selchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem","family":"Salloukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104459_bib0066","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.3135","article-title":"Disease activity after cladribine immune reconstitution therapy: to repeat or to retreat?","volume":"98","author":"Allen-Philbey","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104459_bib0014","first-page":"551","article-title":"Relapse-free and neda status with cladribine in a real life population: a multicentre study","volume":"26","author":"Annovazzi","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0031","article-title":"Two year relapse-free and NEDA status with Cladribine in a real-life population: a multicentre study","volume":"27","author":"Annovazzi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0015","first-page":"274","article-title":"Early real-world safety, tolerability, and efficacy of cladribine tablets: a single center experience","volume":"26","author":"Bain","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118113","article-title":"Real world experience with cladribine at S. Andrea hospital of Rome","volume":"429","author":"Barbuti","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104459_bib0017","article-title":"Effectiveness of cladribine in multiple sclerosis \u2013 clinical experience of two tertiary centers","volume":"26","author":"Barros","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0052","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.104459_bib0060","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/psp4.12796","article-title":"Predicting disease activity in patients with multiple sclerosis: an explainable machine-learning approach in the Mavenclad trials","volume":"11","author":"Basu","year":"2022","journal-title":"CPT Pharmacome. Syst. Pharmacol."},{"key":"10.1016\/j.msard.2022.104459_bib0067","first-page":"35","article-title":"Cladribine tablets\u2019 potential role as a key example of selective immune reconstitution therapy in multiple sclerosis","volume":"8","author":"Boyko","year":"2018","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.msard.2022.104459_bib0037","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.1370","article-title":"Comparative effectiveness of cladribine versus fingolimod in the treatment of highly active relapsing multiple sclerosis: The MERLYN (MavEnclad Real worLd comparative efficacY non-iNterventional) study","volume":"98","author":"Brownlee","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104459_bib0038","article-title":"Real-world experience with cladribine in the MSBase registry","volume":"27","author":"Butzkueven","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0049","article-title":"Outcomes after late Cladribine re-dosing in the Australian MSBase cohort","author":"Butzkueven","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0018","article-title":"Cladribine as a treatment of multiple sclerosis, real world experience","volume":"25","author":"Celius","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0019","first-page":"701","article-title":"Real-world evidence of immune reconstitution therapies: use of Cladribine and Alemtuzumab in Chile","volume":"27","author":"Ciampi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0003","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0051","article-title":"Rates of lymphopenia year-by-year in patients with relapsing multiple sclerosis treated and retreated with cladribine tablets 3.5 mg\/kg","author":"Cook","year":"2017","journal-title":"ECTRIMS\/ACTRIMS 2017 Poster (P666)"},{"key":"10.1016\/j.msard.2022.104459_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/13524585211010294","article-title":"Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY extension studies","volume":"28","author":"De Stefano","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0045","article-title":"Cladribine: 14 years atrophy and clinical follow-up","author":"Dive","year":"2020","journal-title":"Eur. Charcot Found."},{"key":"10.1016\/j.msard.2022.104459_bib0030","article-title":"Cladribine in a real world setting. The real patients","volume":"27","author":"Eichau","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0039","first-page":"629","article-title":"Treatment patterns prior to and post cladribine in patients with multiple sclerosis","volume":"29","author":"Ellenberger","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0020","article-title":"A swedish post-market surveillance study: long-term effectiveness and safety of cladribine tablets (IMSE 10) for patients treated at least 12 months","volume":"26","author":"Forsberg","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.664596","article-title":"Opportunities and obstacles associated with sequential immune reconstitution therapy for multiple sclerosis: a case report","volume":"12","author":"Garbo","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0068","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.104459_bib0005","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib69","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.1919","article-title":"CLASSIC-MS: long-term efficacy and real-world treatment patterns for patients with relapsing multiple sclerosis who received cladribine tablets in phase III parent trials","volume":"96","author":"Giovannoni","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104459_bib0004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104459_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.1919","article-title":"CLASSIC-MS: long-term efficacy and real-world treatment patterns for patients with relapsing multiple sclerosis who received cladribine tablets in phase III parent trials","author":"Giovannoni","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104459_bib0007","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies","volume":"38","author":"Giovannoni","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2022.104459_bib0010","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","author":"Giovannoni","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0013","article-title":"Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to liver safety","author":"Giovannoni","year":"2022","journal-title":"ECTRIMS"},{"key":"10.1016\/j.msard.2022.104459_bib0061","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/13524585211049392","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study","volume":"28","author":"Giovannoni","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103278","article-title":"Factors associated with fingolimod rebound: a single center real-life experience","volume":"56","author":"Goncuoglu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0021","first-page":"555","article-title":"Oral cladribine in the treatment of multiple sclerosis \u2013 data from the national registry ReMuS\u00ae registry","volume":"86","author":"Hor\u00e1kov\u00e1","year":"2021","journal-title":"Cesk Slov. Neurol. N."},{"key":"10.1016\/j.msard.2022.104459_bib0022","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/1352458517728812","article-title":"Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis","volume":"24","author":"Kalincik","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0056","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1007\/s00415-021-10956-1","article-title":"Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents","volume":"269","author":"Korsen","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0044","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2022.104459_bib0059","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain."},{"key":"10.1016\/j.msard.2022.104459_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419887596","article-title":"Therapy with cladribine is efficient and safe in patients previously treated with natalizumab","volume":"12","author":"M\u00f6hn","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0001","unstructured":"Merck (2022). Mavenclad 10 mg Tablets SmPC. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf (Accessed Dec 2022)."},{"key":"10.1016\/j.msard.2022.104459_bib0064","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2022.104459_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00489","article-title":"Single-center 8-years clinical follow-up of Cladribine-treated patients from phase 2 and 3 trials","volume":"11","author":"Moccia","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0040","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.2968","article-title":"A cross-sectional survey evaluating cladribine tablets treatment patterns among patients with multiple sclerosis across the US enrolled in the MS lifelines patient support program","volume":"98","author":"Nicholas","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104459_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0042","article-title":"4-year follow-up of multiple sclerosis patients treated with cladribine: clinical outcomes and third-year course","volume":"29","author":"Oreja-Guevara","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0062","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/aian.AIAN_159_19","article-title":"No evidence of disease activity (NEDA) in multiple sclerosis - shifting the goal posts","volume":"22","author":"Pandit","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0054","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13,","author":"Patti","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0034","article-title":"Predictors of cladribine effectiveness in multiple sclerosis: a real-world, multicenter, two-year follow-up study","volume":"29","author":"Petracca","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0053","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12,","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0002","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","article-title":"The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review","volume":"80","author":"Rammohan","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2022.104459_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215207","article-title":"Long-term safety and efficacy of subcutaneous cladribine used in increased dosage in patients with relapsing multiple sclerosis: 20-year observational study","volume":"10","author":"Rejdak","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2022.104459_bib0024","first-page":"701","article-title":"Real world data from the argentine MS national registry of patients under cladribine","volume":"27","author":"Rojas","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0025","article-title":"Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study \u201cimmunomodulation and multiple sclerosis epidemiology 10\u201d (IMSE 10)","volume":"27","author":"Rosengren","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0026","first-page":"588","article-title":"Safety and effectiveness of cladribine in multiple sclerosis \u2013 clinical experience of five tertiary centers","volume":"27","author":"Santos","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102492","article-title":"Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: a systematic review","volume":"19","author":"Sellner","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2022.104459_bib0063","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s13311-017-0548-5","article-title":"Therapeutic targets for multiple sclerosis: current treatment goals and future directions","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2022.104459_bib0058","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12,","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0027","article-title":"Real world experience of oral immune reconstitution therapy (cladribine) in the treatment of multiple sclerosis in the united arab emirates","volume":"26","author":"Thakre","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0012","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/03007995.2020.1865888","article-title":"Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment","volume":"37","author":"Vermersch","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2022.104459_bib0028","article-title":"Characterization of cladribine tablets treated MS patients in Finland","author":"Viitala","year":"2020","journal-title":"Eur. Charcot Found."},{"key":"10.1016\/j.msard.2022.104459_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.11.069","article-title":"Long term effectiveness of Cladribine in patients enrolled in the CLARITY trial: real world experience from the lebanese cohort","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104459_bib0033","article-title":"Efficacy\/safety profile of cladribine in an italian real-life cohort of relapsing remitting multiple sclerosis patients","volume":"28","author":"Zanetta","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104459_bib0035","first-page":"706","article-title":"Relapse during the washout period predicts time to relapse after switching to cladribine","volume":"27","author":"Zhong","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104459_bib0029","first-page":"705","article-title":"Evaluation of therapy satisfaction with cladribine tablets in RMS patients \u2013 final results of the non-interventional study CLEVER","volume":"27","author":"Ziemssen","year":"2021","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:40Z","timestamp":1761901480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":69,"alternative-id":["S2211034822009634"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104459","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104459"}}